Ruixin Pharmaceutical

Ruixin Pharmaceutical is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the discovery and development of innovative small molecule oncology drugs. The company was founded by Dr. Shenghong Zhang, a veteran of the global pharmaceutical industry with significant R&D leadership experience. Its lead drug candidate, RX-108, is a first-in-class small molecule that targets Na+/K+-ATPase and is currently in Phase 2 clinical trials for indications such as recurrent glioblastoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck. Ruixin’s drug discovery strategy focuses on targeting metabolic pathways and ion transporters that are critical for cancer cell survival and growth. The company maintains close operations with its affiliate, Suzhou NeuPharma, to advance its pipeline of novel therapeutic agents.